Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrinogen - Grifols

Drug Profile

Fibrinogen - Grifols

Alternative Names: FIB-Grifols; Fibrinogen human - Grifols; Human plasma-derived fibrinogen concentrate - Grifols

Latest Information Update: 10 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grifols
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Afibrinogenaemia

Most Recent Events

  • 24 Nov 2020 Grifols plans a phase III trial for Afibrinogenaemia (In Children, In Adolescents, In Adults, In Elderly) in December 2023 (NCT04636268)
  • 11 Nov 2019 Grifols completes a phase I/II trial in Afibrinogenaemia in USA, India, Italy, Lebanon (NCT02281500)
  • 29 Aug 2019 Fibrinogen is still in phase I/II trials for Afibrinogenaemia in India, USA (IV) (NCT02281500)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top